Printer Friendly

Compugen names new director and chairman of the board.

M2 PHARMA-August 3, 2017-Compugen names new director and chairman of the board

(C)2017 M2 COMMUNICATIONS

Compugen Ltd (NASDAQ: CGEN), a company involved in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced yesterday that it has named Paul Sekhri as its director and chairman of the board.

As the new chairman, Sekhri will succeed Martin Gerstel, who announced his intention to retire from this role in February of this year.

Sekhri was appointed the president and CEO of Lycera Corporation in February 2015. Prior to joining Lycera, he served as senior vice president, Integrated Care for Sanofi from April 2014 until January 2015. Previously, he served as group executive vice president, Global Business Development and chief strategy officer for Teva Pharmaceutical Industries Ltd. Prior to joining Teva he spent five years as operating partner and head of the Biotechnology Operating Group at TPG Biotech. From 2004-2009, Sekhri was founder, president, and chief executive officer of Cerimon Pharmaceuticals Inc. Prior to founding Cerimon, he was president and chief business officer of ARIAD Pharmaceuticals Inc. Previously, Sekhri spent four years at Novartis, as senior vice president, and head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG. He also developed the Disease Area Strategy for Novartis, identifying those specific therapeutic areas upon which the company would focus. His first role at Novartis was as global head, Early Commercial Development - a department he established to ensure the differential competitive advantage of Novartis' pipeline.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Aug 3, 2017
Words:258
Previous Article:China Biologic reports Q2 2017 unaudited financial results.
Next Article:Hansa Medical announces publication of results from Phase II studies of its lead candidate IdeS in The New England Journal of Medicine.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters